Answers are grounded in this paper and cite their sources.
Randomized trial shows intravenous tranexamic acid decreases intraoperative blood loss in TURP, indicating better postoperative recovery.
Introduction:Benign prostatic hyperplasia (BPH) is a common condition among aging men, often requiring transurethral resection of the prostate (TURP) for symptomatic relief. One of the major intraoperative and postoperative complications of TURPis bleeding, which can lead to increased transfusion rates and higher morbidity. Tranexamic acid (TXA), antifibrinolytic agent, has been used in various surgical settings to minimize blood loss, but its role in TURP remains under investigation. Study aimed to evaluate the efficacy of intravenous TXA in reducing intraoperative blood loss, preserving hemoglobin levels, and improving postoperative recovery in patients undergoing TURP. Materials And Methods: Arandomized controlled trial was conducted at KD Medical College, involving 66 patients undergoing TURPfor BPH. Patients were randomly assigned into two groups: Group A received intravenous TXA, while Group B did not receive TXA. Parameters assessed included intraoperative blood loss and postoperative complications. Results: Group A had significantly lower intraoperative blood loss (149.69 ± 50 ml vs. 296.21 ± 75 ml, p=0.01). Postoperative complications, including fever (p=0.03), clot retention (p=0.01), and transfusion requirements (p=0.01), were lower in the TXA group. Conclusion: Intravenous TXA effectively reduces blood loss and improves postoperative recovery in TURP patients. It minimizes transfusion rates without increasing thromboembolic risks, making it a valuable adjunct in TURPprocedures.
No takes yet. Share an insight, caveat, or question.
N. Singh (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: